MedTrace Logo

Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria

NCT01444196 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-10-03

No results posted yet for this study

Summary

The primary objective of the study is to assess the dosis of DL which is sufficient to inhibit cold urticaria symptoms.

Conditions

  • Urticaria

Interventions

DRUG

Desloratadine

Every day,per mouth,in the evening, for 14 +- 2 days.

Sponsors & Collaborators

  • Johannes Gutenberg University Mainz

    collaborator OTHER

  • Marcus Maurer

    lead OTHER

Principal Investigators

  • Marcus Maurer, Prof. · Charite, University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-04-30
Completion
2010-05-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01444196 on ClinicalTrials.gov